Product Description
Cephradine is a first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton. It has a role as an antibacterial drug. It is a cephalosporin and a beta-lactam antibiotic allergen. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cephradine)
Mechanisms of Action: PBP Inhibitor,Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Bangladesh | Brazil | Chile | China | Colombia | Dominican Republic | Egypt | Hong Kong | India | Indonesia | Ireland | Italy | Korea | Lebanon | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | South Africa | Taiwan | Turkey | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: North China Pharmaceutical Huamin Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Soh-Med-23-09-05MS | N/A |
Recruiting |
Cesarean Section |
2024-07-31 |
|
| ChiCTR2100048623 | N/A |
Not yet recruiting |
Mastitis |
2022-12-31 |
|
| CTR20191692 | N/A |
Completed |
Urinary Tract Infections|Soft Tissue Infections|Respiratory Tract Infections |
2019-09-18 |
|
| CTR20191286 | N/A |
Completed |
Bronchitis|Pharyngitis|Pneumonia|Soft Tissue Infections|Tonsillitis|Otitis Media |
2019-08-30 |